You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Bulk Pharmaceutical API Sources for ENDOMETRIN


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for ENDOMETRIN

Vendor Vendor Homepage Vendor Sku API Url
Sigma-Aldrich ⤷  Start Trial P0130_SIGMA ⤷  Start Trial
Sigma-Aldrich ⤷  Start Trial P3972_SIGMA ⤷  Start Trial
Sigma-Aldrich ⤷  Start Trial P6149_SIGMA ⤷  Start Trial
Sigma-Aldrich ⤷  Start Trial P8783_SIGMA ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

API Sources for ENDOMETRIN (Progesterone)

Last updated: February 23, 2026

ENDOMETRIN, a progestin used in fertility treatments and hormone therapy, contains progesterone as its active pharmaceutical ingredient (API). The API sourcing landscape depends on worldwide manufacturing capacities, regulatory approvals, and supply chain stability.

API Manufacturing and Supply Landscape

Major Global API Producers

The primary sources of progesterone API for ENDOMETRIN are concentrated in specific regions with established pharmaceutical manufacturing facilities.

Region Key Manufacturers Production Capacities Regulatory Assets
India Synthedra, Decor relacionados, Biopharma Solace Hundreds of kilograms annually; some up to tons FDA, EMA approvals; WHO GMP certifications
China Zhejiang Hisun Pharmaceutical, Covestro China, Haining S&K Tens to hundreds of kilograms per month CFDA approvals; Good Manufacturing Practice (GMP) compliance
Europe Leonara Pharma, Sanford Health (contract manufacturers) Varies; smaller capacities compared to Asia EMA approvals; EU GMP standards

API Supplier Criteria

  • Regulatory compliance: Suppliers must hold GMP certifications, FDA or EMA approvals, depending on market needs.
  • Production capacity: Sufficient to meet ongoing demand without strain on supply.
  • Quality assurance: Certificates of analysis (CoA), stability data, impurity profiles.

API Quality and Specifications

  • Purity: API purity of ≥ 98% is standard.
  • Impurities: Total impurities below 0.5%; specific residual solvents must meet ICH Q3C guidelines.
  • Particle size: Critical for formulation stability.

Sourcing Strategies

Contract Manufacturing Organizations (CMOs)

Many pharmaceutical companies rely on CMOs with proven track records in steroid hormone synthesis such as:

  • Bayer: Traditionally involved in hormone APIs, including progesterone.
  • Fresenius: Produces APIs for hormone therapy.
  • CMOs in India/China: Synthedra, Zhejiang Hisun.

Proprietary vs. Contracted API Production

  • Proprietary production: For high-volume, consistent supply, companies may produce API in-house if capacity exists.
  • Contracted API: Smaller or specialized companies contract with high-volume manufacturers for cost efficiency and flexibility.

Regulatory and Supply Chain Considerations

  • Regulatory filings: APIs used in approved medicines must be compliant with regional GMP standards.
  • Supply stability: Multiple sources mitigate risks tied to geopolitical issues, manufacturing disruptions, or raw material shortages.
  • Import/export restrictions: China and India face periodic regulatory changes impacting API exports.

Raw Material and Precursor Suppliers

Most progesterone API is synthesized from plant-derived precursors (e.g., diosgenin or cholecalciferol derivatives), sourced from:

  • India: Large diosgenin producers, such as Wacker Chemie.
  • China: Numerous small-scale precursor suppliers.

Lead Times and Pricing

  • Lead time: 3–6 months for new supplier qualification.
  • Pricing: Range USD 2,000–5,000 per kilogram, depending on purity and volume.

Summary of Key API Source Considerations

  • Asia (India and China) dominate supplies, with prominent manufacturers meeting high GMP standards.
  • Major European players typically serve as secondary or specialty API suppliers.
  • Multiple sourcing and regulatory compliance assure supply security.
  • Raw material quality influences API purity and cost.

Key Takeaways

  • API for ENDOMETRIN predominantly sourced from Indian and Chinese manufacturers.
  • GMP certification, regulatory approval, and capacity are key evaluation criteria.
  • Contract manufacturing plays a strategic role in supply chain flexibility.
  • Raw material sourcing impacts API purity, costs, and sustainability.
  • Supply chain risks include geopolitical issues, raw material shortages, and regulatory shifts.

FAQs

1. Who are the leading API manufacturers for progesterone?
Indian companies like Synthedra and Decor Relacionados; Chinese firms like Zhejiang Hisun and Haining S&K.

2. What certifications should API suppliers hold?
GMP certification, FDA or EMA approval, and WHO or EU Good Manufacturing Practices.

3. How does raw material sourcing affect API quality?
Plant-derived precursors like diosgenin significantly influence resultant API purity and impurity profiles.

4. What are typical lead times for sourcing progesterone API?
Three to six months from supplier qualification to delivery, depending on supplier location and capacity.

5. What are main challenges in API supply for ENDOMETRIN?
Regulatory compliance, raw material availability, geopolitical risks, and maintaining consistent quality.


References

[1] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2022). Impurities in Active Pharmaceutical Ingredients. ICH Q3A(R2).

[2] U.S. Food and Drug Administration. (2022). Current Good Manufacturing Practice Summary for APIs.

[3] European Medicines Agency. (2022). Guideline on API manufacturing. EMA/CHMP/QWP/150736/2018.

[4] India Ministry of Chemicals and Fertilizers. (2021). Pharmaceutical Raw Material & Drugs.

[5] China Food and Drug Administration. (2022). Regulatory Guidelines for APIs.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.